Contains fulltext : 201379.pdf (publisher's version ) (Open Access
Background Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and...
Background: Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the...
Objective. The aim of the study was to conduct clinical economic analysis of aflibercept (AFL) treat...
BACKGROUND:The discussion on the use of bevacizumab is still ongoing and often doctors are deterred ...
<div><p>Background</p><p>The discussion on the use of bevacizumab is still ongoing and often doctors...
Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society ...
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenes...
PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as...
Background: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibe...
BACKGROUND: Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients wit...
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Base...
PURPOSE: To present a computerized model assessing individualized cost utility for current treatment...
Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and blindness....
Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These ...
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD)....
Background Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and...
Background: Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the...
Objective. The aim of the study was to conduct clinical economic analysis of aflibercept (AFL) treat...
BACKGROUND:The discussion on the use of bevacizumab is still ongoing and often doctors are deterred ...
<div><p>Background</p><p>The discussion on the use of bevacizumab is still ongoing and often doctors...
Age-related macular degeneration (AMD) is a blinding disease placing considerable burden on society ...
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenes...
PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as...
Background: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibe...
BACKGROUND: Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients wit...
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Base...
PURPOSE: To present a computerized model assessing individualized cost utility for current treatment...
Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and blindness....
Purpose Ophthalmologists increasingly depend on new drugs to advance their treatment options. These ...
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD)....
Background Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and...
Background: Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the...
Objective. The aim of the study was to conduct clinical economic analysis of aflibercept (AFL) treat...
DOI
Add to ORKG